Spectral expands sales of heart test:
This article was originally published in Clinica
Executive Summary
Spectral Diagnostics has expanded the European sales of its STATus point-of-care heart attack tests following the signing of three distribution agreements. Medixon will sell the tests in Israel, where it is based, as well as in Cyprus and Jordan. Greece and Turkey will be handled by Median*s agent Gerolymatos. Intex will sell the kits in Hungary, while Slovakia and the Czech Republic are to be served by Aris Jicin. The two STATus tests detect troponin-I, and CK-MB and Myoglobin.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.